Portage Biotech (NASDAQ:ALP) Stock: Insider Fiorenzo Villani Purchases 5,150 Shares

Portage Biotech Inc. (NASDAQ:ALP) insider Fiorenzo Villani purchased 5,150 shares of the business’s stock in a transaction on Wednesday, October 7th. The stock was purchased at an average cost of $3.80 per share, with a total value of $19,570.00. Following the acquisition, the insider owned 54,036 shares in the company, valued at approximately $205,336.80. This represents a 10.53% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Fiorenzo Villani also recently made the following trade(s):

• On Tuesday, September 22nd, Fiorenzo Villani acquired 10,000 shares of Portage Biotech stock. The stock was purchased at an average price of $4.40 per share, with a total value of $44,000.00.
• On Wednesday, September 16th, Fiorenzo Villani acquired 4,265 shares of Portage Biotech stock. The shares were purchased at an average cost of $4.05 per share, for a total transaction of $17,273.25.
• On Tuesday, September 15th, Fiorenzo Villani acquired 7,900 shares of Portage Biotech stock. The shares were purchased at an average cost of $4.15 per share, for a total transaction of $32,785.00.
• On Tuesday, September 15th, Fiorenzo Villani acquired 10,382 shares of Portage Biotech stock. The shares were purchased at an average price of $4.07 per share, for a total transaction of $42,254.74.
• On Monday, September 14th, Fiorenzo Villani bought 2,000 shares of Portage Biotech stock. The stock was purchased at an average price of $4.16 per share, with a total value of $8,320.00.
• On Wednesday, September 9th, Fiorenzo Villani bought 7,000 shares of Portage Biotech stock. The stock was purchased at an average price of $5.07 per share, with a total value of $35,490.00.

Portage Biotech Stock Down 4.3%

Shares of ALP stock opened at $3.80 on Tuesday. The stock has a market cap of $5.89 million, a P/E ratio of -0.01 and a beta of 0.63. Portage Biotech Inc. has a one year low of $3.20 and a one year high of $389.00. The stock has a fifty day moving average price of $6.38 and a 200 day moving average price of $12.68. The company has a debt-to-equity ratio of 0.01, a current ratio of 0.31 and a quick ratio of 0.31.

Portage Biotech (NASDAQ:ALP) last announced its quarterly earnings results on Thursday, July 16th. The company reported $23.75 earnings per share (EPS) for the quarter. The business had revenue of $0.05 million during the quarter. Analysts predict that Portage Biotech Inc. will post -14.00 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ALP. Zacks Research upgraded shares of Portage Biotech to a “hold” rating in a research report on Tuesday, August 18th. HC Wainwright assumed coverage on shares of Portage Biotech in a research note on Monday, August 17th. They issued a “neutral” rating and a $12.50 target price on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Portage Biotech in a research report on Friday, July 24th. Finally, Wall Street Zen raised shares of Portage Biotech to a “hold” rating in a research report on Saturday, September 12th. Two analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Reduce” and an average target price of $12.50.

Portage Biotech Company Profile

Portage Biotech Inc is a clinical-stage biotechnology company focused on developing immuno-oncology therapies for patients with solid tumors. The company’s approach is designed to stimulate the immune system and directly target tumor cells, with the goal of addressing cancers that are resistant or unresponsive to existing treatments.

Portage’s lead investigational product is INT230-6, an intratumoral therapy based on a proprietary formulation designed to deliver anticancer agents directly into tumors.